Product Overview
PuraPly® Antimicrobial (PuraPly® AM) Wound Matrix is an FDA 510(k)-cleared Class II medical device that is indicated for the management of a variety of acute and chronic wound types, including partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, trauma wounds, draining wounds, and first- and second-degree burns.
PuraPly Antimicrobial Wound Matrix (PuraPly AM) consists of a collagen sheet coated with 0.1% polyhexmethylenebiguanide hydrochloride (PHMB) intended for the management of wounds. PuraPly AM is supplied dry in sheet form. The device is packaged in sterile, sealed single pouches.
PuraPly AM utilizes a purified native collagen matrix embedded with the antimicrobial polyhexamethylene biguanide, or PHMB, a broad spectrum antimicrobial. It is this combination of native collagen and PHMB that helps manage the reformation of biofilm while supporting healing across a wide variety of wound types, regardless of severity or duration.
Launched in 2016, PuraPly AM is part of BBWM™, a proactive approach which aims to reduce and manage the reformation of biofilm with sharp debridement and the use of PuraPly AM.
PuraPly AM has been named one of the “Top 10 Innovations in Podiatry” by Podiatry Today, a publication that covers the latest developments in podiatric medicine.
For more information on PuraPly AM please visit www.puraplyam.com.
(https://organogenesis.com)
